Effects of early administration of atorvastatin treatment on thrombotic process in normocholesterolemic patients with unstable angina

International Journal of Cardiology

Volumn 106, Issue 3, 2006, Pages 333-337

  Tousoulis, Dimitris ^a   Bosinakou, Erini ^a   Kotsopoulou, Maria ^a   Antoniades, Charalambos ^a   Katsi, Vasiliki ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute coronary syndromes; Statins; Thrombosis; Unstable angina

Indexed keywords

ANTITHROMBIN III; ATORVASTATIN; BLOOD CLOTTING FACTOR 5; PROTEIN C; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD PROTEINS; CHOLESTEROL; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRROLES;

EID: 28844455978     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.02.011     Document Type: Article

References (35)

1. K.W. Lee, and G.Y. Lip Acute coronary syndromes: Virchow's triad revisited Blood Coagul Fibrinolysis 14 2003 605 625
2. B.F. Becker, B. Heindl, C. Kupatt, and S. Zahler Endothelial function and hemostasis Z Kardiol 89 2000 160 167
3. A. Manten, R.J. de Winter, and M.C. Minnema Procoagulant and proinflammatory activity in acute coronary syndromes Cardiovasc Res 40 1998 389 395
4. The LIPID Investigators Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
5. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
6. D.R. Illingworth, and J.A. Tobert A review of clinical trials comparing HMG-CoA reductase inhibitors Clin Ther 16 1994 366 385
7. R.S. Blumenthal Statins: effective antiatherosclerotic therapy Am Heart J 139 2000 577 583
8. V. Di Garbo, R. Cordova, and G. Avellone Increased thrombin generation and complement activation in patients with type II hyperlipoproteinemia: effects of simvastatin treatment Curr Ther Res 58 1997 706 723
9. J. Dupuis, J.C. Tardif, P. Cernacek, and P. Theroux Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the REFICE (reduction of cholesterol in ischemia and function of endothelium) trial Circulation 99 1999 3227 3233
10. E.S. Stroes, H.A. Koomans, T.W. de Bruin, and T.J. Rabelink Vascular function in the forearm of hypercholesterolemic patients off and on lipid-lowering medication Lancet 346 1995 457 471
11. C.B. Treasure, J.L. Klein, and W.S. Weintraub Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease N Engl J Med 332 1995 481 487
12. J. Malyszko, T. Urano, R. Knofler, H. Ihara, Y. Takada, and A. Takada Relationships between serum lipids serotonin platelet aggregation and some fibrinolytic parameters in humans Life Sci 55 1994 1619 1623
13. K.A. Mitropoulos Lipids-thrombosis interface Br Med Bull 50 1994 813 832
14. R.S. Rosnenson, C.C. Tangney, and L.C. Casey Inhibition of proinflammatory cytokine production by pravastatin Lancet 353 1999 983 984
15. O. Grip, S. Janciauskiene, and S. Lindgren Pravastatin down-regulates inflammatory mediators in human monocytes in vitro Eur J Pharmacol 410 2000 83 92
16. M. Romano, A. Mezzetti, and C. Marulli Fluvastatin reduces soluble P-selectin and ICAM-1 levels in hypercholesterolemic patients: role of nitric oxide J Invest Med 48 2000 183 189
17. E. Braunwald Unstable angina-a classification Circulation 80 1989 410 414
18. E. Braunwald, E.M. Antman, and J.W. Beasley ACC/AHA guidelines for the management of patients with unstable angina non-ST segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the management of patients with unstable angina) J Am Coll Cardiol 36 2000 970 1062
19. T.W. Meade, S. Mellows, and M. Brozovic Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study Lancet ii 1986 533 537
20. E. Morishita, H. Jokaji, and T. Matsuda Hyperlipidemia and hemostatic system J Atheroscler Thromb supp 1 1995 S36 S40
21. S. Kinlay, and A.P. Selwyn Effects of statins on inflammation in patients with acute and chronic coronary syndromes Am J Cardiol 91 supp 2003 9B 13B
22. N.E. Nielsen, A. Siegbahn, and E. Swahn Markers of hypercoagulation and von Willebrand factor in postmenopausal women with unstable coronary artery disease. Discriminatory ability regarding unstable coronary artery disease and coronary atherosclerosis using receiver operating characteristics J Intern Med 248 2000 151 158
23. T. Bourcier, and P. Libby HMG-CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells Arterioscler Thromb Vasc Biol 20 2000 556 562
24. W.H. Kaesemeyer, R.B. Caldwell, J. Huang, and R.W. Caldwell Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions J Am Coll Cardiol 33 1999 234 241
25. U. Laufs, V.L. Fata, J. Plutzky, and J.K. Liao Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors Circulation 97 1998 1129 1135
26. R. Krysiak, B. Okopien, and Z. Herman Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes Drugs 63 2003 1821 1854
27. F. Bruni, A.L. Pasqui, and M. Pastorelli Effect of atorvastatin on different fibrinolyis mechanisms in hypercholesterolemic subjects Int J Cardiol 95 2004 269 274
28. The 4S Investigators Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S) Lancet 344 1994 1383 1389
29. F.M. Sacks, M.A. Pfeffer, and L.A. Moye The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol level N Engl J Med 335 1996 1001 1009
30. The MIRACL Investigators Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study JAMA 285 2001 1711 1718
31. C.P. Cannon, E. Braunwald, and C.H. McCabe Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
32. D.D. Waters, G.G. Schwartz, A.G. Olsson MIRACL Study Investigators Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction. A myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy Circulation 106 2002 1690 1695
33. G. Dangas, J.J. Badimon, and D.A. Smith Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile J Am Coll Cardiol 33 1999 1294 1304
34. A. Szczeklik, J. Musial, and A. Undas Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia J Am Coll Cardiol 33 1999 1286 1293
35. U. Rauch, J.I. Osende, and J.H. Chesebro Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins Atherosclerosis 153 2000 181 189